Acellera is a London/Barcelona based company focused on providing new technologies for the study of biophysical phenomena. For the past 7 years, Acellera’s R&D programme has focused on developing software and hardware solutions that optimize the efficiency and throughput of molecular dynamics simulations. Our first innovation, ACEMD, demonstrated accelerator processors (GPUs) as an entry to high efficiency computing for MD simulations, and furnished personal workstations with cluster-computer levels of performance at a fraction of the cost.
Acellera leverages the power of GPUs to enable molecular dynamics simulations in high-throughput. Whether in-house (Metrocubo), or over the cloud (AceCloud), Acellera’s technology delivers efficient solutions for biotechnology research, including the discovery of active small molecules using the fragment approach. The binding studies by Acellera, which computationally yields binding constants, poses, pathways and kinetic constants with a level of detail and accuracy that is unique worldwide, is one such representation.
- Area of Activity
- Scientific & Technical instruments
- Software development
- Company type
- Technology Services
Devonshire House, 582 Honeypot Lane,
Stanmore, Middlesex HA7 1JS, GB
Calle Dr. Trueta 183, 7º-5º
Barcelona, Barcelona 08005, ES
Matthew Harvey / Chief Technology Officer
Gianni de Fabritiis / Chief Science Officer
Franck Chevalier / Business and Scientific Developer
The services provided by Acellera focus on offering molecular simulations and others computational approaches that improve the effectiveness of drug development. Principally, we propose applications to automatize the study of molecular conformational change and the binding process of molecules.
- Design and development of Software and Hardware
- In-silico solutions for drug discovery
- Cloud computing
- Research and development
Acellera's research has led to more than 25 articles since 2009. Presently, the tools developed are used in hundreds of groups across the world. Acellera participates in several European projects. Its services are recognized by the largest pharmaceutical companies and currently collaborate closely with several in Europe and The United States.
Research groups across universities, non profit organizations, pharmaceutical companies, biotechnology companies.